Arthneeti
AP

Aptus Pharma Ltd

Q1 FY27Pharmaceuticals & Biotechnology

Aptus Pharma Q1 FY27: Revenue ₹32.20 Cr, PAT ₹2.87 Cr

Q1 FY27 investor presentation: what the company reported on revenue, margins and projects.

Price₹347
Market cap₹606 Cr
P/E131.2
Updated25 Sept 2026
Read4 min read

Based on Aptus Pharma Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.

The short version

Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) - Revenue for H1 FY26: ₹14.38 crore, up 123.9% QoQ from H2 FY25 (Page 23) - Revenue for FY26: ₹4 Quarter (H2 FY26) Financials (Page 23): - EBITDA: ₹4.49 crore, up 56.3% YoY from ₹2.88 crore - EBITDA Margin: 14.0%, down from 19.4% YoY - PAT: ₹2.87 crore, up 60.1% YoY from ₹1.79 crore

From Aptus Pharma Ltd's Q1 FY27 earnings-call transcript · updated 25 Sept 2026.

Revenue & Sales Performance

  • Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23)
  • Revenue for H1 FY26: ₹14.38 crore, up 123.9% QoQ from H2 FY25 (Page 23)
  • Revenue for FY26: ₹46.57 crore, up 89.7% YoY from ₹24.56 crore in FY25 (Page 26)
  • No explicit volume figures stated in the presentation
  • Outlook: Strategic growth roadmap targets Pan-India presence by March 2029 and global expansion by March 2028 across Asia, Africa, and Latin America (Page 28)

2 more points management made on revenue & sales performance

Profitability & Margins

See what Aptus Pharma Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Aptus Pharma follows an asset-light contract manufacturing model and does not own manufacturing facilities, relying on WHO-GMP-certified partners (Page 14).
  • The company has formal loan and licence agreements with two manufacturing units in Gujarat (Page 14).
  • Strategic Growth Roadmap aims for own manufacturing to constitute 20% by March 2028, strengthening quality control and supply-chain (Page 28).
  • Proposed manufacturing expansion targeted by March 2028 (Page 28).

2 more points management made on capital expenditure plans

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

5x potential
1KRM Ayurveda Ltd
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Aptus Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The investor presentation does not provide any specific data or mention regarding the order book, order inflow, or pending orders. It focuses primarily on: - Financial performance highlights (revenue, EBITDA, PAT) - Business model and strategic focus areas - Key milestones and portfolio expansion

2 more points management made on order book & pipeline

Continue your research

What Aptus Pharma Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • RPG Life Sciences Ltd (Q1 FY27)

    Q1 FY27 Revenue from Operations: ₹195.7 crores, up 15.8% YoY (Q1 FY26: ₹168.9 crores) [Page 18] . Key concall takeaways from RPG Life Sciences Ltd's Q1 FY27…

  • SMS Pharmaceuticals Ltd (Q1 FY27)

    Q1FY27 revenue from operations: ₹207 crore, up 6% YoY (Page 6, 5) . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY27 earnings call — and how it…

  • Wanbury Ltd (Q1 FY27)

    Q4FY26 Revenue from Operations: ₹164.58 Crore . Key concall takeaways from Wanbury Ltd's Q1 FY27 earnings call — and how it ranks against sector peers.

  • Symbiotec Pharmalab Ltd (Q1 FY27)

    Q1 FY27 consolidated revenue from operations: ₹218.2 crores, up 7% YoY from ₹203.2 crores in Q1 FY26 (Page 9). Key concall takeaways from Symbiotec Pharmalab…

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Aptus Pharma Ltd Q1 FY27 results?

Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) - Revenue for H1 FY26: ₹14.38 crore, up 123.9% QoQ from H2 FY25 (Page 23) - Revenue for FY26: ₹4 Quarter (H2 FY26) Financials (Page 23): - EBITDA: ₹4.49 crore, up 56.3% YoY from ₹2.88 crore - EBITDA Margin: 14.0%, down from 19.4% YoY - PAT: ₹2.87 crore, up 60.1% YoY from ₹1.79 crore

What is Aptus Pharma Ltd share price analysis?

Aptus Pharma Ltd currently shows a neutral. The stock trades at a P/E of 131.2 with a market cap of ₹606 Cr. Investors should review the full earnings analysis for detailed insights.

Is Aptus Pharma Ltd planning capital expenditure?

Aptus Pharma follows an asset-light contract manufacturing model and does not own manufacturing facilities, relying on WHO-GMP-certified partners (Page 14).

Keep Aptus Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.